Biogen: Phase 2/3 DEVOTE Study Supports Clinical Benefits Of High-dose Regimen Of nusinersen

February 04, 2026 — 08:23 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Biogen (BIIB) announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating the high-dose regimen of nusinersen, comprised of 50 mg/5 mL loading and 28 mg/5 mL maintenance doses, in spinal muscular atrophy. The company said the results showed the safety and effectiveness of the high-dose regimen of nusinersen across a broad range of people living with SMA, irrespective of age, prior treatment experience, and baseline functional status.

The high-dose regimen of SPINRAZA or nusinersen is approved in the European Union and Japan. The high-dose regimen is under review with the FDA and has a PDUFA action date of April 3.

In pre-market trading on NasdaqGS, Biogen shares are up 0.53 percent to $177.69.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Biogen: Phase 2/3 DEVOTE Study Supports Clinical Benefits Of High-dose Regimen Of nusinersen

Tags

Latest Articles